Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Edwards Lifesciences's average EBITDA Per Share Growth Rate was -8.10% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was -2.70% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 5.60% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 9.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Edwards Lifesciences was 57.80% per year. The lowest was -24.10% per year. And the median was 12.15% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Edwards Lifesciences 3-Year EBITDA Growth Rate Related Terms
WBO:EWLS vs BSX, DXCM, GEHC: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Edwards Lifesciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -2.70% mean?
Edwards Lifesciences (WBO:EWLS) has a 3-Year EBITDA Growth Rate of -2.70% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Edwards Lifesciences and its competitors. According to the industry distribution chart, Edwards Lifesciences ranks #473 out of 692 companies in the Medical Devices & Instruments industry, placing it in the top 68.4%.
Is Edwards Lifesciences' 3-Year EBITDA Growth Rate too high?
Edwards Lifesciences' current 3-Year EBITDA Growth Rate is -2.70%. Based on the distribution chart, Edwards Lifesciences ranks #473 out of 692 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Edwards Lifesciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' 3-Year EBITDA Growth Rate compare to BSX and DXCM?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #473 out of 692 companies for 3-Year EBITDA Growth Rate. This places Edwards Lifesciences in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Edwards Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current 3-Year EBITDA Growth Rate is -2.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (WBO:EWLS) is currently considered Fairly Valued. The stock's GF Value™ is €81.70, compared to a current price of €77.72 — trading 4.9% below its estimated fair value. The current 3-Year EBITDA Growth Rate is -2.70%. Edwards Lifesciences' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Edwards Lifesciences (WBO:EWLS), the current 3-Year EBITDA Growth Rate is -2.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (WBO:EWLS) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of €77.72 is trading 4.9% below its estimated GF Value™ of €81.70.
GuruFocus considers Edwards Lifesciences to be Fairly Valued.
Key valuation signals for WBO:EWLS:
3-Year EBITDA Growth Rate: -2.70%
GF Value™: €81.70 vs. price of €77.72 (4.9% below fair value)
No single metric tells the full story. See the WBO:EWLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
94GF Score
Get the complete analysis for WBO:EWLS
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:EWLS has been successfully added to your 
